Navigation Links
Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
Date:3/16/2009

ASHBURN, Va., March 16 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the first of two ongoing U.S. phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the prevention of surgical site infections.

The trial is being conducted at approximately 50 hospital sites across the U.S. and has enrolled 1,500 diabetic and/or obese (BMI>30) patients undergoing cardiac surgery. Such patients are generally recognized to be at higher risk of developing sternal wound infections (SWI); a serious and potentially life-threatening complication of cardiac surgery. Patients in the treatment group have two Gentamicin Implants (260 mg total dose) placed between the sternal halves before chest closure and the primary endpoint is total incidence of SWI after 3 months post-surgery. The trial design was based on a published 2,000 patient clinical trial performed in Sweden which demonstrated that the implant significantly reduced the incidence of sternal wound infection (SWI) by 53 percent, increasing to 68 percent reduction in the higher risk patient population. A health economic analysis of the Swedish study has also been published and concluded that routine prophylactic use of the Gentamicin Implant resulted in a net cost saving per patient.

Patient enrolment in a second phase 3 trial being conducted in patients undergoing open colorectal surgery is expected to close later this month. Innocoll has appointed Duke University's Duke Clinical Research Institute (DCRI) as the Study Coordinating Center for both phase 3 trials.

Dr. Michael Myers, Innocoll's President and CEO commented, "We are delighted to have completed patient enrolment in this phase 3 cardiac surgery trial, which we are running in parallel with the second phase 3 trial in colorectal s
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
2. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
4. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
5. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
6. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
8. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
9. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
10. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
11. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013   Voices Against Brain Cancer ... for brain cancer, today announced that it has awarded ... the clinical investigation of Toca 511 & Toca FC ... brain cancer (Grade 3 or Grade 4).  Tocagen is ... advanced cancer, with an initial focus on brain cancer. ...
(Date:6/19/2013)... , June 19, 2013 Amerivet Solutions, ... servicing all branches of government from Federal to ... expanded their facilities to include complex metal design ... fabricated some very complex aluminum parts for the ... expand our capabilities to service government contracts," states ...
(Date:6/19/2013)... PLAINS, N.Y. , June 19, 2013  This ... supporting more than 300 research projects with one goal ... And in 2013, "Team In Training" (TNT), a flagship ... endurance sports training program, is marking its landmark 25 ... invest more than $875 million in research to discover ...
Breaking Medicine Technology:Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Amerivet Solutions Expands to Manufacture Complex Metal Designs 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 3Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 4Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 5
... N.J., June 15, 2011 Cordis Corporation, ... interventional vascular technology, today announced it will no longer ... in order to focus on other cardiovascular therapies where ... the manufacture of CYPHER® and CYPHER SELECT® Plus Sirolimus-Eluting ...
... American Academy of Family Physicians Foundation is excited ... Award winners. These awards recognize family medicine residency ... their communities through creative solutions. Monetary grants and ... presented to 16 residents from the following programs: ...
Cached Medicine Technology:Cordis Announces Discontinuation of NEVO™ Sirolimus-Eluting Coronary Stent 2Cordis Announces Discontinuation of NEVO™ Sirolimus-Eluting Coronary Stent 3Cordis Announces Discontinuation of NEVO™ Sirolimus-Eluting Coronary Stent 4Family Medicine Residency Programs Recognized for Improving Childhood and Adult Immunizations Rates in Underserved Communities 2Family Medicine Residency Programs Recognized for Improving Childhood and Adult Immunizations Rates in Underserved Communities 3
(Date:6/19/2013)... Chicago, IL (PRWEB) June 19, 2013 Brand new ... Pakulski for the 4 day sale on the Hypertrophy Max program. ... the next 24 hours so those that are interested must act ... The all new Hypertrophy Max bonus is a free 12 month ... Del Monte. , According to Ryan Davids "Live Large TV is ...
(Date:6/19/2013)... A man returning from war is not likely to ... his debut book titled RED DANCER JOURNEY, author Rafael Fraguada pens ... home, looking for the right place and people to mend his ... from the Vietnam War, returns to New York City, he meets ... Wings, a wealthy acquaintance from a tiny Midwest college they both ...
(Date:6/19/2013)... WV (PRWEB) June 19, 2013 The ... individual used the sauna but the overall experience for ... to be positive health-wise. , Mr Mouw, whose Virgina-based ... to the Society’s statement by saying that the type ... learned of a number of counterfeit imitations which frankly, ...
(Date:6/19/2013)... New York, NY (PRWEB) June 19, 2013 ... at Mount Sinai demonstrated several new studies at ... Expo (ENDO) from June 15-18 in San Francisco.     ... self-management, as well as the role of prostastic acid ... new molecules that can stimulate the thyroid gland; revealed ...
(Date:6/19/2013)... June 19, 2013 CCA , ... Dr. John Baxter to Vice President, Health Services, effective ... Director, Mental Health Services for CCA. He will ... honor and great privilege to lead CCA's dedicated team ... opportunity to serve society and our partners as we ...
Breaking Medicine News(10 mins):Health News:New Hypertrophy Max Bonus Just Released and Only Available for 24 Hours 2Health News:Rafael Fragauda’s New Book Underlines Post Traumatic Stress Disorder 2Health News:Health Benefits of Saunas Only Viable with Properly Constructed Models, Warns Manufacturer 2Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 2Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 3Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 4Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 5Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 6Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 7Health News:CCA Names Dr. John Baxter Vice President, Health Services 2
... serious concern over growing problems due to use of ... Empowerment Meira Kumar today suggested effective monitoring // and ... ,There is a need to establish effective drug use ... the northeastern region,Kumar said while releasing a monograph on ...
... cholesterol-decreasing medications like millions of Americans. However she does ... she is taking part in a different clinical study ... view the benefits of Lipitor on the immune system ... sclerosis (ALS). ,Physicians at the Methodist NI's ...
... 24 years, bled to death following delivery of a stillborn baby, ... mother’s death, would now be offered a ?300,000 compensation for the ... duty in her case. ,She was admitted to the ... told that her baby had passed away in the uterus and ...
... business model for the state-of-the-art Institute of Liver and Biliary ... ,The model approved by the Cabinet at its meeting ... to be self-sufficient in nine years' time, an official spokesman ... medical equipment would be borne by Delhi Government., ,The ...
... ,The effects of zolpidem on three patients were studied for ... rehabilitation experts reveal that they are in a condition where ... interaction and responses, having signs of movement, sleep and breathing ... the patients every morning. ,An improvement was seen ...
... be a ray of hope for men, who are holed ... from available treatment measures//. An exercise by scientists involving rabbits, ... engineer an artificial penis, may be the answer for non-treatable ... adult male rabbits were introduced with a graft made from ...
Cached Medicine News:Health News:Study Aims At The Immune System In Patients With Lou Gehrig's Disease 2Health News:?300,000 Compensation For Family After Death Of Daughter Following Deliver 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: